About 50 million of the US adult population suffer from chronic pain. It is a complex disease
in its own right for which currently available analgesics have been deemed woefully …

Alterations in signalling due to bidirectional transactivation of G protein-coupled receptor
(GPCRs) and receptor tyrosine kinases (RTKs) are well established. Transactivation …

Chronic pain has been widely recognized as a major public health problem that impacts
multiple aspects of patient quality of life. Unfortunately, chronic pain is often resistant to …

In addition to analgesia, opioids produce opioid-induced hyperalgesia (OIH) and
neuroplasticity characterized by prolongation of inflammatory-mediator-induced …

Morphine is frequently applied in cancer patients for pain management. However, its effects
on cancer are not well understood but observed to be specific to certain cancer types. We …

Chronic pain is a debilitating disorder that can occur as painful episodes that alternates with
bouts of remission and occurs despite healing of the primary insult. Those episodes are …

Systemic fentanyl induces hyperalgesic priming, long-lasting neuroplasticity in nociceptor
function characterized by prolongation of inflammatory mediator hyperalgesia. To evaluate …

Stimulation of the mu-opioid receptor (MOR) on nociceptors with fentanyl can produce
hyperalgesia (opioid-induced hyperalgesia, OIH) and hyperalgesic priming, a model of …

Clinical µ-opioid receptor (MOR) agonists produce hyperalgesic priming, a form of
maladaptive nociceptor neuroplasticity, resulting in pain chronification. We have established …

Opioid-induced hyperalgesia (OIH) is a serious adverse event produced by opioid
analgesics. Lack of an in vitro model has hindered study of its underlying mechanisms …